Fed Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 36
- Registration Number
- NCT01019590
- Locations
- 🇺🇸
PRACS Institute Ltd., Fargo, North Dakota, United States
Fasting Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 36
- Registration Number
- NCT01020214
- Locations
- 🇺🇸
PRACS Institute Ltd., Fargo, North Dakota, United States
Fed Study of Mylan Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg and Macrobid® Capsules 100 mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 80
- Registration Number
- NCT01018342
- Locations
- 🇺🇸
Kendle International Inc., Morgantown, West Virginia, United States
Fasting Study of Alendronate Sodium Tablets (70 mg) and Fosamax Tablets (70 mg)
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2009-11-13
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 110
- Registration Number
- NCT01012934
- Locations
- 🇺🇸
PRACS Insitute Ltd., Fargo, North Dakota, United States
Bioequivalence Study of Nisoldipine Extended-Release Tablets, 30 mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-09-28
- Last Posted Date
- 2009-09-28
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 78
- Registration Number
- NCT00985660
- Locations
- 🇺🇸
PRACS Institute Ltd., Fargo, North Dakota, United States
Fasting Study of Alendronate Sodium Tablets (10 mg) and Fosamax Tablets (10 mg)
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-09-24
- Last Posted Date
- 2009-09-24
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 112
- Registration Number
- NCT00983996
- Locations
- 🇺🇸
PRACS Insitute Ltd., Fargo, North Dakota, United States
Single-Dose Fed Bioequivalence Study of Nisoldipine Extended-Release Tablets (40 mg; Mylan) and Sular® Extended-Release Tablets (40 mg; First Horizon) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2009-09-18
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 83
- Registration Number
- NCT00979537
- Locations
- 🇺🇸
Pracs Institute, Ltd, Fargo, North Dakota, United States
Fasting Study of Liothyronine Sodium Tablets (50 Mcg) to Cytomel® Tablets (50 Mcg)
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2009-09-16
- Last Posted Date
- 2009-09-16
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 31
- Registration Number
- NCT00978055
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Fasting Bioequivalence Study of Nisoldipine Extended-Release Tablets 40 mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: VoSpire® ER Tablets 8 mg
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2008-08-08
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 48
- Registration Number
- NCT00730197
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Fed Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 23
- Registration Number
- NCT00650013
- Locations
- 🇺🇸
Kendle International Inc., Morgantown, West Virginia, United States
© Copyright 2025. All Rights Reserved by MedPath